Literature DB >> 28700044

Prevalence of and risk factors for multidrug-resistant tuberculosis in Iran and its neighboring countries: systematic review and meta-analysis.

Worku Jimma1,2,3, Marjan Ghazisaeedi4, Leila Shahmoradi4, Ahmed Abdulahi Abdurahman3,5, Sharareh Rostam Niakan Kalhori4, Mahshid Nasehi6,7, Sharifi Yazdi8, Reza Safdari4.   

Abstract

Tuberculosis, in particular drug-resistant tuberculosis, is of global concern due to the high mortality and morbidity associated with it annually. The aim of this study was to determine the prevalence of and the risk factors for multidrug-resistant tuberculosis in Iran and its neighboring countries. Four databases (PubMed, BioMed Central, EMBASE, and Web of Science) were searched using key terms. Nineteen eligible articles were identified, of which 12 and seven were used for quantitative and qualitative analysis, respectively. The overall pooled estimate of the prevalence of multidrug-resistant tuberculosis, including both new and previously treated tuberculosis cases, in Iran, Iraq, Turkey and Pakistan was 16% (95% confidence interval [CI] 11-20). The patients with a previous tuberculosis treatment history (odds ratio [OR] = 6.45; 95% CI 5.12-7.79), those aged <45 years (OR = 1.57; 95% CI 1.12-2.03), and those who were males (OR = 1.83; 95% CI 1.19-2.48) had an increased pool risk of developing multidrug-resistant tuberculosis. The forest plot revealed that the pooled odds for the development of multidrug- resistant tuberculosis were 2.01 (95% CI 1.65-2.36). Poor adherence to treatment was one of the predictors of unsuccessful treatment outcomes. Multidrug-resistant tuberculosis is a great concern for public health programs in many countries globally, including those included in this review. The risk factors for the development of multidrug-resistant tuberculosis, specifically a previous tuberculosis treatment history, should be targeted through the implementation of specialized interventions.

Entities:  

Mesh:

Year:  2017        PMID: 28700044     DOI: 10.1590/0037-8682-0002-2017

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  6 in total

1.  Prevalence and Drug Resistance Pattern of Mycobacterium tuberculosis Isolated from Tuberculosis Patients in Basra, Iraq.

Authors:  Khairallah A S Mohammed; Ghorob S Khudhair; Dheyaa Bekheet Al-Rabeai
Journal:  Pol J Microbiol       Date:  2022-05-31

2.  Determining Mycobacterium tuberculosis Drug Resistance and Risk Factors for Multidrug-Resistant Tuberculosis in Sputum Smear-Positive Tuberculosis Outpatients in Anhui Province, China, 2015-2016.

Authors:  Song Yao; Junwei Yan; Ling Li; Dongchun Ma; Jie Liu; Qing Wang; Aimin Wang; Fangjin Bao; Zekun Zhang; Xundi Bao
Journal:  Infect Drug Resist       Date:  2020-04-09       Impact factor: 4.003

3.  Tuberculosis in Iran: a historical overview from al-Tabari, Rhazes, Avicenna and Jorjani to Abolhassan Ziyā-Zarifi. Old and new pioneers in the fight against tuberculosis: challenges, pitfalls and hopes.

Authors:  Ma Behzadifar; M Martini; Me Behzadifar; N L Bragazzi
Journal:  J Prev Med Hyg       Date:  2020-04-30

4.  Is latent tuberculosis infection challenging in Iranian health care workers? A systematic review and meta-analysis.

Authors:  Mohammad Hossein YektaKooshali; Farahnaz Movahedzadeh; Ali Alavi Foumani; Hoda Sabati; Alireza Jafari
Journal:  PLoS One       Date:  2019-10-03       Impact factor: 3.240

5.  Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana.

Authors:  Blackson Pitolo Tembo; Ntambwe Gustav Malangu
Journal:  BMC Infect Dis       Date:  2019-09-06       Impact factor: 3.090

6.  Spatio-temporal epidemiology of the tuberculosis incidence rate in Iran 2008 to 2018.

Authors:  Behzad Kiani; Amene Raouf Rahmati; Robert Bergquist; Soheil Hashtarkhani; Neda Firouraghi; Nasser Bagheri; Elham Moghaddas; Alireza Mohammadi
Journal:  BMC Public Health       Date:  2021-06-07       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.